{"SPADE_N_14396": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_N_14396", "Peptide Name": "Ar-1-(C/A) (Arenicin-1 analog C3A,C20A, synthetic AMPs, linear, UCLL1: Derivative: ARlin)", "Source": "amino acid substitution, animal-derived, natural derivative", "Family": "Not found", "Gene": "Not found", "Sequence": "RWAVYAYVRVRGVLVRYRRAW", "Sequence Length": 21, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram+", "Anti-Gram-"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 2696.17, "PI": 11.72, "Hydrophobicity": -0.14, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Krenev IA, Umnyakova ES, Eliseev IE, Dubrovskii YA, Gorbunov NP, Pozolotin VA, Komlev AS, Panteleev PV, Balandin SV, Ovchinnikova TV, Shamova OV, Berlov MN. 2020", "Reference": "Mar Drugs. 2020 Dec 10;18(12):631. doi: 10.3390/md18120631.PubMed", "Title": "Antimicrobial Peptide Arenicin-1 Derivative Ar-1-(C/A) as Complement System Modulator."}], "Frequent Amino Acids": "RVA", "Absent Amino Acids": "CDEFHIKMNOPQSTU", "Basic Residues": 6, "Acidic Residues": 0, "Hydrophobic Residues": 14, "Polar Residues": 17, "Positive Residues": 6, "Negative Residues": 0, "Net Charge": 6, "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (90.48%) toArenicin-1R: 29%, V: 24%, A=Y: 14%.Activity: active against E. coli (MIC 4.0 uM) and L. monocytogenes (MIC 3.6 uM). The MIC values are comparable to Ar-1 (3.3 and 2.2 uM, respectively).In vitro toxicity: minimal hemolytic concentration (MHC) 11.1 uM, which is higher than that of Ar-1 (MHC 2.9 uM).SAR: linearization of  the peptide via iodoacetamidated cysteine did not affect peptide activity clearly but lienar peptide appeared to be less toxic (Orlov et al., 2019).", "Similar Sequences": [{"SPADE_ID": "SPADE_UN_24772", "Similarity": 1.0, "Sequence": "RWAVYAYVRVRGVLVRYRRAW"}, {"SPADE_ID": "SPADE_UN_17458", "Similarity": 0.9473684210526315, "Sequence": "RWVYAYVRVRGVLVRYRRW"}, {"SPADE_ID": "SPADE_N_02759", "Similarity": 0.9047619047619048, "Sequence": "RWCVYAYVRVRGVLVRYRRCW"}]}}}